Home | Contact Us 

Online Catalog

View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at

How Can We Help You?
Click here to contact us!


Sepragen Corporation Announces The Addition of K. Charles Janac To Its Board of Directors

Union City, CA, July 11, 2000 - Sepragen Corporation (OTC BB: SPGNU, SPGNA, SPGNW) a provider of patented technology and equipment for purification needs in the nutritional and biotech industries, today announced the appointment of K. Charles Janac to its Board of Directors. Mr. Janac is a 13D shareholder of Sepragen’s common stock.

Vinit Saxena, Chairman and CEO of Sepragen Corporation stated “Charlie Janac is a dynamic builder of businesses with a proven track record in Silicon Valley.” He added, “His experience as an executive and a strategist and his entrepreneurial spirit are greatly welcomed on the Sepragen Board.”

Mr. Janac started his career as a polymer chemist with the Exxon Chemical Company. He was a co-founder of Cadence Design Systems (NYSE:CDN) helping to build it into one of the top ten software companies in the world. Following Cadence Design Systems, he was the President of High Level Design Systems. He then formed Smart Machines, which he recently sold to Brooks Automation (NASDAQ:BRKS) where he is responsible for the atmospheric automation equipment business used in semiconductor and disk drive manufacturing. Mr. Janac holds a BS and MS degree in Organic Chemistry from Tufts University and an MBA from Stanford Graduate School of Business.

“I am pleased to be joining the board of Sepragen Corporation,” said Mr. Janac, he added, “Sepragen is one of the most meaningful companies I know in terms of positive impact on society. “It is a technology leader in enabling pharmaceuticals and neutraceuticals reach volume production”.

Sepragen Corporation develops and markets technology along with equipment and supplies for process chromatography applications. Sepragen has developed a number of patented applications that provide large market opportunities in the food and beverage industry, including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as well as extracting proteins from whey. The company holds over 14 issued patents relating to its core technology. As of December 31, 1999, Sepragen had 5,412,562 common shares issued.

Return to News Archives main page

The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2020 Sepragen Corporation. All rights reserved. (510) 475-0650